Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) (NASDAQ: MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/MYGN.

Investigation Details

On October 31, 2024, it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025. Specifically, market analysts reported that a document from UnitedHealth stated that the coverage is ending as tests for behavioral health, which includes GeneSight, are “unproven” and “not medically necessary.” On this news, Myriad’s stock price fell sharply during intraday trading on November 1, 2024.

What's Next?

If you are aware of any facts relating to this investigation or purchased Myriad securities, you can assist this investigation by visiting the firm’s site: bgandg.com/MYGN. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241114821947/en/